PT - JOURNAL ARTICLE AU - Paramita, Swandari AU - Isnuwardana, Ronny AU - Duma, Krispinus AU - Bakhtiar, Rahmat AU - Nuryanto, Muhammad Khairul AU - Pramulia Yudia, Riries Choiru AU - Fitriany, Evi AU - Aminyoto, Meiliati TI - Characteristics of COVID-19 fatality cases in East Kalimantan, Indonesia AID - 10.1101/2020.08.01.20166470 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.01.20166470 4099 - http://medrxiv.org/content/early/2020/08/04/2020.08.01.20166470.short 4100 - http://medrxiv.org/content/early/2020/08/04/2020.08.01.20166470.full AB - Introduction Coronavirus Disease (COVID-19) is caused by SARS-CoV-2 infection. On March 2, 2020, Indonesia announced the first confirmed cases of COVID-19 infection. East Kalimantan will play an important role as the new capital of Indonesia. There is attention to the preparedness of East Kalimantan to respond to COVID-19. We report the characteristics of COVID-19 fatality cases in here.Methods We retrospectively analyzed the fatality cases of COVID-19 patients from the East Kalimantan Health Office information system. All patients were confirmed COVID-19 by RT-PCR examination.Results By July 31, 2020, 31 fatality cases of patients had been identified as having confirmed COVID-19 in East Kalimantan. The mean age of the patients was 55.1 ± 9.2 years. Most of the patients were men (22 [71.0%]) with age more than 60 years old (14 [45.2%]). Balikpapan has the highest number of COVID-19 fatality cases from all regencies. Hypertension was the most comorbidities in the fatality cases of COVID-19 patients in East Kalimantan.Discussion Older age and comorbidities still contributed to the fatality cases of COVID-19 patients in East Kalimantan, Indonesia. Hypertension, diabetes, cardiovascular disease, and cerebrovascular disease were underlying conditions for increasing the risk of COVID-19 getting into a serious condition.Conclusion Active surveillance for people older than 60 years old and having underlying diseases is needed for reducing the case fatality rate of COVID-19 in East Kalimantan.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author received no financial support for the research and/or publication of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethical Health Research Commission of Faculty of Medicine Mulawarman University, Samarinda, East Kalimantan, Indonesia.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.